Labcorp (LH) to Spin Off Clinical Development Business
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Labcorp to Spin Off Clinical Development Business
July 28, 2022 6:59 AM EDTClinical Development Business to be a Leading, Pure-Play Contract Research Organization with a Comprehensive Set of Clinical Trial Management, Market Access and Technology Capabilities
Labcorp Remains a Leader in the Laboratory Market with Highly Complementary, Laboratory-Focused Businesses including Routine and Esoteric Labs, Central Labs and Early Development Research Labs
Transaction Designed to Create Value Through Enhanced Strategic and Operational Focus
Labcorp to Discuss Spin-off and Second Quarter 2022 Financial Results at 9:00 a.m. ET Today
BURLINGTON, N.C.--(BUSINESS... More
